Session

Radiation therapy for prostate cancer

Poster Session 54

  • Location:
    Room 14c (ICM, Level 1)
  • Chairs:
     D. Basic, Nis (RS)
     R. Ganzer, Leipzig (DE)
     R.J. Karnes, Rochester (US)
  • Aims and objectives of this session

    Radiation therapy, its outcome and its morbidity for localised prostate cancer patients will be discussed in this session. An interesting prospective randomised trial comparing robotic prostatectomy and brachytherapy will be discussed.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
672
Long term outcomes of prostate brachytherapy in Japan and recurrence predictors

By: Yagi Y.1, Aoki K.1, Nakamura K.1, Hasegawa M.1, Ozu C.1, Nishiyama T.1, Shiraishi Y.2, Toya K.3, Yorozu A.4, Saito S.1

Institutes: 1Tokyo Medical Center, Dept. of Urology, Tokyo, Japan, 2Keio University, Dept. of Radiation Oncology, Tokyo, Japan, 3International University of Health and Welfare, Mita Hospital, Dept. of Radiation Oncology, Tokyo, Japan, 4Tokyo Medical Center, Dept. of Radiation Oncology, Tokyo, Japan

673
Long term 15 years disease free data of LDR brachytherapy in 1700 consecutive men

By: Matzkin H.1, Agai R.1, Strauss N.2, Meir Y.2, Mabjeesh N.1

Institutes: 1Tel-Aviv Medical Center, Dept. of Urology, Tel Aviv, Israel, 2Tel-Aviv Medical Center, Dept. of Oncology, Tel Aviv, Israel

674
Quality of Life (QoL) in patients with locally advanced prostate cancer treated with neoadjuvant endocrine, external beam radiation and adjuvant continuous/intermittent endocrine therapy in an open-label, randomized, phase III trial

By: Yokomizo A.1, Koga H.2, Ito K.3, Suzuki K.3, Yamanaka H.4, Naito S.2

Institutes: 1Kyushu University Graduate School of Medical Sciences, Dept. of Urology, Fukuoka, Japan, 2Harasanshin Hospital, Dept. of Urology, Fukuoka, Japan, 3Gunma University Graduate School of Medicine, Dept. of Urology, Maebashi, Japan, 4Kurosawa Hospital, Dept. of Urology, Takasaki, Japan

675
Urethral strictures after radiotherapy for prostate cancer - 5 year data of a certified prostate-cancer-centre

By: Kranz J.1, Maurer G.2, Maurer U.2, Deserno O.1, Steffens J.1

Institutes: 1St.-Antonius-Hospital, Dept. of Urology, Eschweiler, Germany, 2MVR RNR Eschweiler, Eschweiler, Germany

676
Prospective evaluation of urinary function in patients with prostate cancer treated with external beam radiation therapy

By: Badenchini F.2, Cozzarini C.1, Avuzzi B.2, Fodor A.1, Noris Chiorda B.1, Rancati T.2, Sini C.3, Valdagni R.2, Di Muzio N.1, Fiorino C.3

Institutes: 1San Raffaele Scientific Institute, Dept. of Radiotherapy, Milan, Italy, 2Fondazione IRCCS Istituto Nazionale Dei Tumori, Dept. of Radiotherapy, Milan, Italy, 3San Raffaele Scientific Institute, Dept. of Medical Physics, Milan, Italy

677
Oncological outcomes in patients with locally advanced prostate cancer treated with neoadjuvant endocrine and external beam radiation therapy followed by adjuvant continuous/intermittent endocrine therapy in an open-label, randomized, phase III trial

By: Ito K.1, Suzuki K.1, Yamanaka H.2

Institutes: 1Gunma University Graduate School of Medicine, Dept. of Urology, Maebashi, Japan, 2Kurosawa Hospital, Institute for Preventive Medicine, Takasaki, Japan

678
External beam radiotherapy with or without androgen deprivation therapy in very elderly patients with high metastatic risk prostate cancer

By: Dell’Oglio P.1, Leyh-Bannurah S-R.2, Tian Z.3, Trudeau V.1, Larcher A.4, Fossati N.4, Moschini M.4, Sosa J.1, Capitanio U.4, Briganti A.4, Graefen M.2, Montorsi F.4, Saad F.5, Karakiewicz P.1

Institutes: 1Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Dept. of Urology, Montreal, Canada, 2Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 3McGill University, Dept. of Epidemiology, Biostatistics and Occupational Health, Montreal, Canada, 4Irccs Ospedale San Raffaele, Dept. of Oncology, Unit of Urology, Uri, Milan, Italy, 5University of Montreal Health Center, Dept. of Urology, Montreal, Canada

679
The incidence and risk of biochemical recurrence following radical radiotherapy for prostate cancer in men on angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARB)

By: Alashkham A., Paterson C., Nabi G.

Institutes: Ninewells Hospital, Dundee, United Kingdom

680
Whole pelvis intensity-modulated arc therapy for lymph node metastasized prostate cancer: Oncologic outcomes and prognostic factors

By: Poelaert F.1, Fonteyne V.2, Claeys T.1, Ost P.2, Decaestecker K.1, De Meerleer G.2, D’Hondt B.1, De Visschere P.3, Lumen N.1

Institutes: 1Universitair Ziekenhuis Gent, Dept. of Urology, Ghent, Belgium, 2Universitair Ziekenhuis Gent, Dept. of Radiation Oncology, Ghent, Belgium, 3Universitair Ziekenhuis Gent, Dept. of Radiology, Ghent, Belgium

681
Risk of second malignancies after iodine-125 prostate brachytherapy as monotherapy in a single institution

By: Fernandez A.1, Bucci J.1, Malouf D.2, Wong K.1, Chin Y.1, Browne L.3

Institutes: 1St George Hospital Cancer Care Centre, Dept. of Radiation Oncology, Kogarah, Australia, 2St George Hospital Cancer Care Centre, Dept. of Urology, Kogarah, Australia, 3St George Hospital Cancer Care Centre, Dept. of Statistics, Kogarah, Australia

682
Clinico-dosimetric factors predicting long-term severe urinary incontinence after post-prostatectomy RT: Results of a longitudinal observational study

By: Noris Chiorda B.1, Sini C.2, Fiorino C.2, Briganti A.3, Chiara A.1, Deantoni C.1, Fossati N.3, Gandaglia G.3, Suardi N.3, Montorsi F.3, Di Muzio N.1, Cozzarini C.1

Institutes: 1San Raffaele Scientific Institute, Dept. of Radiotherapy, Milan, Italy, 2San Raffaele Scientific Institute, Dept. of Medical Physics, Milan, Italy, 3San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy

* 683
Prospective randomized study comparing robotic prostatectomy versus brachytherapy for the treatment of low risk prostate cancer

By: Giberti C., Gallo F., Schenone M., Cortese P., Gastaldi E., Becco D.

Institutes: San Paolo Hospital, Dept. of Urology, Savona, Italy

684
Could “radical” RT be a reasonable therapeutic option in bone oligometastatic prostate cancer patients?

By: Deantoni C.L.1, Cozzarini C.1, Fodor A.1, Noris Chiorda B.1, Mangili P.2, Picchio M.3, Incerti E.3, Dell’Oca I.1, Passoni P.1, Fiorino C.2, Calandrino R.2, Di Muzio N.1

Institutes: 1IRCCS Ospedale San Raffaele, Dept. of Radiotherapy, Milan, Italy, 2IRCCS Ospedale San Raffaele, Dept. of Medical Physics, Milan, Italy, 3IRCCS Ospedale San Raffaele, Dept. of Nuclear Medicine, Milan, Italy

685
Evaluation of outcomes of salvage robotic prostatectomy: Single surgeon experience

By: Syed J., Christopher C., Kumar A., Samavedi S., Jenson C., Ogaya Pinies G., Ganapathi H., Bates A., Doss J., Rocco B., Coelho R., Mouraviev V., Patel V.

Institutes: Global Robotic Institute, Dept. of Urology, Celebration, United States of America